The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data

Abstract

Summary Background Early immunotherapy administration improves outcomes in patients with N-methyl-D-aspartate receptor (NMDAR)-antibody encephalitis. As most patients with NMDAR-antibody encephalitis present to psychiatrists, the psychopathology of NMDAR-antibody encephalitis needs to be clearly defined to encourage accurate clinical identification and prompt treatment. Methods For this systematic review, we searched PubMed for all studies published in English between Jan 1, 2005, and Oct 7, 2017, to identify individually reported adult patients (≥18 years) who satisfied consensus criteria for definite NMDAR-antibody encephalitis. After generating a list of 50 fine-grained, lower-level features, we extracted psychopathological data in addition to demographic and aetiological data. The lower-level features were later ordered within higher-level categories. As a means of quality control, we filtered the data according to proxy markers of psychiatric involvement in their description. Subsequently, we compared lower-level features from individual patient data with operationalised psychiatric syndromes using a constrained combination approach and principal component analysis, and did a network analysis to explore the inter-relationships between multiple lower-level features. The review protocol was prospectively registered with PROSPERO, number CRD42017068981. Findings Of 1096 records identified in PubMed, 333 satisfied inclusion criteria and described 1100 patients in total with NMDAR-antibody encephalitis. The psychopathology of 505 (46%) patients with reported psychiatric symptoms was described in more detailed terms than only psychiatric or behavioural. 464 (91%) of the 505 patients were from papers in which patient data were reported individually. The remainder of the analyses focused exclusively on these 464 patients. Median age was 27 years (IQR 22–34), 368 (79%) of 464 patients were female and in 147 (32%), NMDAR-antibody encephalitis was associated with ovarian teratoma. The five higher-level categories into which the 464 patients most frequently grouped were behaviour (316 [68%]), psychosis (310 [67%]), mood (219 [47%]), catatonia (137 [30%]), and sleep disturbance (97 [21%]). The overall pattern of lower-level features was statistically stable across subgroups classified by age, sex, pregnancy association, presence of ovarian teratoma, prior herpes simplex virus encephalitis, and isolated psychiatric presentations (two-way ANOVA p=0·6–0·9). Constrained combination and principal component analyses found that mixtures of mood and psychosis syndromes fit each patient better than any single diagnosis alone, particularly for the patients in the psychiatric-described subgroup (mean ΔAkaike information criterion −0·04 in non-psychiatric-described subgroup vs 0·61 in psychiatric-described subgroup). The overlapping nature of the higher-level features was also enriched upon analysis of the psychiatric-d...

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

“…These drugs have also been shown to exacerbate a similarly wide spectrum of symptoms in individuals with schizophrenia, in contrast to amphetamines, which predominantly worsen positive symptoms. Furthermore, it has been shown that anti‐NMDA receptor encephalitis may be associated with psychiatric presentations that resemble schizophrenia in some individuals. NMDA antagonism has, therefore, been proposed to be a superior pharmacological model of schizophrenia, compared to amphetamines, given its ability to more reliably induce negative as well as positive symptoms.…”

Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

“…• • NMDAR, VGKR other receptor autoantibodies (the prevalence of these antibodies is potentially of the order of 1-5% but the actual prevalence of the antibodies or the disorders, and the effect of treatment, are not yet clear: Al-Diwani et al, 2019;Pollack et al, 2014;Rickards et al, 2014). • • Consider lumbar puncture (e.g.…”

Worldwide survey of neurologists on approach to autoimmune encephalitis

“…For example, in NMDAR antibody encephalitis, central psychopathologic features of mood and psychotic disorders consistently coexist within individual patients, although wellcontrolled prospective studies are needed to further advance this approach. 10 The definition of acceptable treatment delay and "red flag" symptoms also requires further evidence-based clarification. For example, a recent cohort study found that delays to treatment longer than 4 weeks and lack of improvement in that time frame were both independently associated with poor 1-year functional outcome, in addition to intensive care unit admission, abnormal MRI, and CSF white blood cell count >20 cells/μL.…”